Thalomid Capsule
Product Images NDC 59572-205

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Thalomid (NDC 59572-205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celgene Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure Of Thalidomide (Thalomid 01)

Chemical structure of thalidomide, the active ingredient in Thalomid capsules, as depicted in the diagram showing its molecular arrangement.*

FDA Label Image

Figure 1: Kaplan-meier Plot Of Time To Disease Progression (Thalomid 02)

A Kaplan-Meier plot displaying the proportion of subjects with no disease progression over time in weeks. It compares two treatment groups: Thal/Dex (solid line) versus Placebo/Dex (dashed line), with censored data points marked. The plot highlights survival without progression between 0 and 160 weeks.*

FDA Label Image

50 mg Blister Pack (Thalomid 03)

Packaging label for Thalomid (thalidomide) 50 mg capsules by Celgene Corporation. The label includes warnings about severe birth defects, dispensing instructions, and usage precautions. It shows the proprietary name, generic name, strength, dosage form as oral capsules, and package size of 28 capsules. The label also displays FDA-mandated information such as pregnancy risk warnings and instructions to dispense in a sealed container.*

FDA Label Image

50 mg Carton (Thalomid 04)

Thalomid 50 mg oral capsules packaging label from Celgene Corporation. The label shows multiple panels including the product name, generic name thalidomide, and strength 50 mg. It details the package contents as 10 blister packs each containing 28 capsules for a total of 280 capsules. The label includes pharmacy dispensing instructions, warnings about serious birth defects and venous thromboembolic events, storage conditions, and the National Drug Code (NDC) 59572-205-94.*

FDA Label Image

50 mg (Single Unit Blister Pack)

Thalomid 50 mg capsules (thalidomide) packaging label, an oral prescription drug manufactured by Celgene Corporation. The label includes warnings about severe, life-threatening birth defects, dispensing instructions for certified pharmacies under the THALOMID REMS program, and prescribing details. Packaging displays product name, strength, dosage form, barcode, and regulatory information.*

FDA Label Image

50 mg (Single Unit Carton)

Thalomid (thalidomide) 50 mg oral capsules packaging label from Celgene Corporation. The label indicates 10 blister packs, each containing 1 capsule, for a total of 10 capsules. It includes dispensing instructions, warnings about severe, life-threatening birth defects and thromboembolic events, storage conditions, and prescribing information. The capsules are described as white, opaque 50 mg with specific imprinting and a 'Do Not Get Pregnant' logo.*

FDA Label Image

100 mg Blister Pack (Thalomid 07)

Thalomid 100 mg capsules label for oral use by Celgene Corporation, featuring detailed prescribing information, birth defect warnings, REMS program instructions, and a child-resistant blister pack with 28 capsules. The label emphasizes the REMS enrollment, dispensing limits, and necessary patient counseling to prevent severe birth defects associated with thalidomide.*

FDA Label Image

100 mg Carton (Thalomid 08)

Packaging label for Thalomid 100 mg capsules by Celgene Corporation, showing a carton that contains 5 blister packs with 28 capsules each (total 140 capsules). The label includes dispensing instructions emphasizing the need to dispense blister packs intact with enclosed prescribing information, along with safety warnings related to severe birth defects associated with Thalidomide use during pregnancy.*

FDA Label Image

150 mg Blister Pack (Thalomid 09)

Thalomid 150 mg capsules (thalidomide) oral medication container label from Celgene Corporation. The label includes patient warnings about birth defects, REMS program details, dispensing instructions limited to certified pharmacies, and important safety information. The design features dosing and packaging instructions, safety icons, a tamper-evident seal, and the Celgene logo.*

FDA Label Image

150 mg Carton (Thalomid 10)

Packaging label for Thalomid 150 mg capsules (thalidomide) by Celgene Corporation. The label indicates a total of 112 capsules supplied in 4 blister packs, each containing 28 capsules. It includes storage instructions, warnings about severe birth defects, dosage form as oral capsules, and prescribing information guidance. The product is marked as Rx only.*

FDA Label Image

200 mg Blister Pack (Thalomid 11)

Thalomid 200 mg (thalidomide) capsules by Celgene Corporation. The label includes four capsules per card and detailed warnings including risks of severe birth defects, requirements for certified pharmacy dispensing, and strict patient guidance. It highlights precautions, directions to avoid pregnancy, and comprehensive safety and usage instructions for this prescription oral capsule drug.*

FDA Label Image

200 mg Carton (Thalomid 12)

Thalomid (thalidomide) 200 mg capsule carton label by Celgene Corporation. The label states the product contains 3 blister packs with 28 capsules each, totaling 84 capsules. It includes warnings about severe birth defects and venous thromboembolic events. The label instructs pharmacists to dispense blister packs intact with enclosed prescribing information and medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.